These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 32854335)

  • 21. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero E; Del Arco RTS; Peña-Asensio J; de Villalobos ES; Míquel J; Larrubia JR
    World J Gastroenterol; 2018 May; 24(17):1825-1838. PubMed ID: 29740199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
    Boglione L; De Benedetto I; Lupia T; Cusato J; Cariti G; Di Perri G
    Arch Virol; 2021 Apr; 166(4):1125-1131. PubMed ID: 33580380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.
    Cai D; Pan C; Yu W; Dang S; Li J; Wu S; Jiang N; Wang M; Zhang Z; Lin F; Xin S; Yang Y; Shen B; Ren H
    Medicine (Baltimore); 2019 Jan; 98(1):e13983. PubMed ID: 30608440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
    Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
    J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
    PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
    Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
    J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
    Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.
    Pereira CV; Tovo CV; Grossmann TK; Mirenda H; Dal-Pupo BB; Almeida PR; Mattos AA
    Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):252-7. PubMed ID: 27074254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
    Brahmania M; Brouwer WP; Hansen T; Mazzulli T; Feld J; Wong D; Kowgier M; Janssen HL
    J Viral Hepat; 2016 Dec; 23(12):1003-1008. PubMed ID: 27502526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
    Liaw YF; Chien RN
    Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.